HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
yVQezMhqjBJF4pgT